EUVIMEDEUVIMED entdecken
Crossref

Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?—that is the question

Jacqueline Trouillas, Pia Burman iD, Marco Losa iD, Ann McCormack iD, Stephan Petersenn, Vera Popovic, Marily Theodoropoulou, Olaf M Dekkers, Gerald Raverot iD

European Journal of Endocrinology · 2023

DOI: 10.1093/ejendo/lvad042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Endocrinology, 2023. Verfasst von Jacqueline Trouillas und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of medicine Lyon-Est, University Claude Bernard Lyon 1, Lyon 69372, France. Hauptthemen laut MEDLINE: Pituitary Neoplasms, Carcinoma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Ipsen, Rare Diseases/Endocrinology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

From a cohort of 171 patients comprising 121 aggressive pituitary tumours (APT) and 50 pituitary carcinomas (PC), the clinicopathological or five-tiered classification based on tumour invasion and proliferation evaluated by at least 2 proliferative markers over the cut-offs (Ki-67 ≥3% or ≥10%, p53 positive or expressed in %, mitotic count >2%), could be applied on 43 tumours: 20 PC and 23 APT. At the initial surgery, 29/43 tumours (67.4%) were grade 2b (invasive and proliferative) of which 44.8% developed metastases during follow-up (PC, grade 3). Out of these 29 tumours, 55.1% had a Ki-67 ≥10%, and were classified grade 2b* (invasive and highly proliferative). There was one tumour grade 1b* (non-invasive and highly proliferative) which metastazed. Out of the 43 tumours, 30.2 % were grade 2a (invasive and non-proliferative). The sensitivity and the specificity of grade 2b for the diagnosis of APT at the initial surgery, were 68% and 90% respectively. The comparison of the high percentage (67.4%) of grade 2b tumours in this selected cohort of APT/PC with the low percentage (8.8%) in a surgical cohort of unselected tumours shows that the initial pathological diagnosis of grade 2b tumour may be considered, in the clinic, as representing a diagnosis of APT. In addition, a significant subgroup of tumours, which will develop metastases supports the proposal that an aggressive grade 2b tumour is “a tumour with malignant potential” or “a malignant tumour without metastases”. So, the clinician may take into account the pathological diagnosis, at the initial surgery, to propose a strict follow-up and to consider earlier use of radiotherapy and/or of temozolomide in the presence of tumours with aggressive behaviour.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pituitary NeoplasmsCarcinomaHumansDacarbazineTemozolomide

Substanzen

DacarbazineTemozolomide

Autor:innen und Institutionen

  • Faculty of medicine Lyon-Est, University Claude Bernard Lyon 1, Lyon 69372, France.
  • Department of Endocrinology, Skåne University Hospital, Malmö, Lund University, Malmö 214 28, Sweden.
  • Department of Neurosurgery, IRCCS San Raffaele, Vita-Salute University, Milan 20132, Italy.
  • Department of Endocrinology, St. Vincent's Hospital, Sydney 2010, Australia.
  • ENDOC Center for Endocrine Tumors, Erik-Blumenfeld-Platz 27a, Hamburg 22587, Germany.
  • School of Medicine, University of Belgrade, Belgrade 11000, Serbia.

ORCID-Profile: Pia Burman, Marco Losa, Ann McCormack, Gerald Raverot

Förderung

  • Ipsen
  • Rare Diseases/Endocrinology

Zitieren

APA

Trouillas, J., Burman, P., Losa, M., McCormack, A., Petersenn, S., Popovic, V., Theodoropoulou, M., Dekkers, O. M., & Raverot, G. (2023). Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?—that is the question. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvad042

Vancouver

Trouillas J, Burman P, Losa M, McCormack A, Petersenn S, Popovic V, et al. Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?—that is the question. European Journal of Endocrinology. 2023. doi:10.1093/ejendo/lvad042

BibTeX
@article{Trouillas2023,
  author = {Trouillas, Jacqueline and Burman, Pia and Losa, Marco and McCormack, Ann and Petersenn, Stephan and Popovic, Vera and Theodoropoulou, Marily and Dekkers, Olaf M and Raverot, Gerald},
  title = {Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?—that is the question},
  journal = {European Journal of Endocrinology},
  year = {2023},
  doi = {10.1093/ejendo/lvad042}
}
Kostenlos starten →